FINEARTS-HF: Improving outcomes in heart failure with preserved or mildly reduced ejection fraction.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42067229.
- Also identified by DOI 10.3949/ccjm.93a.25081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure, N Engl J Med 2024; 391(16):1475-1485) trial evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with left ventricular ejection fraction 40% or greater. Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84, <i>P</i> = .007), primarily by lowering admissions for heart failure. Finerenone is the first mineralocorticoid receptor antagonist to improve outcomes in this patient population.
Medical subject headings
- Heart Failure
- Stroke Volume
- Mineralocorticoid Receptor Antagonists
- Naphthyridines